Hikma Pharmaceuticals Overview
- Year Founded
-
1978
- Status
-
Public
- Employees
-
9,400
- Stock Symbol
-
HIK
- Investments
-
26
- Share Price
-
$22.06
- (As of Friday Closing)
Hikma Pharmaceuticals General Information
Description
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
Contact Information
Website
www.hikma.comCorporate Office
- 10 Portman Square
- London W1H 6AZ
- England, United Kingdom
Corporate Office
- 10 Portman Square
- London W1H 6AZ
- England, United Kingdom
Hikma Pharmaceuticals Stock Performance
As of 20-Nov-2026, Hikma Pharmaceuticals’s stock price is $22.06. Its current market cap is $4.57B with 207M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $22.06 | $22.18 | $15.79 - $23.67 | $4.57B | 207M | 513K | $1.77 |
Hikma Pharmaceuticals Financials Summary
As of 30-Jun-2026, Hikma Pharmaceuticals has a trailing 12-month revenue of $3.42B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,591,490 | 5,932,545 | 6,591,083 | 6,076,406 |
| Revenue | 3,419,000 | 3,349,000 | 3,127,000 | 2,875,000 |
| EBITDA | 859,000 | 813,000 | 719,000 | 538,000 |
| Net Income | 387,000 | 402,000 | 359,000 | 190,000 |
| Total Assets | 5,830,000 | 5,671,000 | 5,133,000 | 4,680,000 |
| Total Debt | 1,957,000 | 1,604,000 | 1,306,000 | 1,191,000 |
Hikma Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hikma Pharmaceuticals Comparisons
Industry
Financing
Details
Hikma Pharmaceuticals Competitors (28)
One of Hikma Pharmaceuticals’s 28 competitors is Lupin, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lupin | Corporation | Mumbai, India | ||||
| Knight Therapeutics | Corporation | Montreal, Canada | ||||
| Taro Pharmaceutical Industries | Corporate Backed or Acquired | Haifa Bay, Israel | ||||
| Dr. Reddy's | Corporation | Hyderabad, India | ||||
| Sandoz | Corporation | Basel, Switzerland |
Hikma Pharmaceuticals Patents
Hikma Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20100125051-A1 | Parenteral formulations comprising sugar-based esters and ethers | Active | 19-Nov-2008 | ||
| US-8541360-B2 | Parenteral formulations comprising sugar-based esters and ethers | Active | 19-Nov-2008 |
Hikma Pharmaceuticals Signals
Hikma Pharmaceuticals Investments & Acquisitions (26)
Hikma Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Takeda Pharmaceutical (Portfolio of Pharmaceutical Products). The deal was made on 31-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Takeda Pharmaceutical (Portfolio of Pharmaceutical Products) | 31-Dec-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Novugen (Kinase Inhibitor Medication for Cancer) | 17-Apr-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Xellia Pharmaceuticals (US Finished Dosage Form Business and Assets) | 10-Sep-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Rakuten Medical | 06-Mar-2024 | Later Stage VC | Drug Discovery | ||
| Custopharm | 21-Apr-2022 | Merger/Acquisition | Pharmaceuticals |
Hikma Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
28.62 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Hikma Pharmaceuticals Exits (4)
Hikma Pharmaceuticals’s most recent exit was on 17-Sep-2014 from Pharmaceuticals Manufacturing Facilities in Bedford. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Pharmaceuticals Manufacturing Facilities in Bedford | 17-Sep-2014 | Completed |
|
||
| Ben Venue Laboratories | 15-Jul-2014 | Completed |
|
||
| HikmaCure | 18-Sep-2013 | Completed |
|
||
| Unimark Remedies | 15-Apr-2011 | Corporate | Completed |
Hikma Pharmaceuticals Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Hikma France | Puteaux, France | 2021 | |
| Hikma Ventures | London, United Kingdom | 2015 | |
| ribosepharm | Grafelfing, Germany | 1983 | |
| Thymoorgan | Vienenburg, Germany | 1980 |
Hikma Pharmaceuticals FAQs
-
When was Hikma Pharmaceuticals founded?
Hikma Pharmaceuticals was founded in 1978.
-
Where is Hikma Pharmaceuticals headquartered?
Hikma Pharmaceuticals is headquartered in London, United Kingdom.
-
What is the size of Hikma Pharmaceuticals?
Hikma Pharmaceuticals has 9,400 total employees.
-
What industry is Hikma Pharmaceuticals in?
Hikma Pharmaceuticals’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Hikma Pharmaceuticals a private or public company?
Hikma Pharmaceuticals is a Public company.
-
What is Hikma Pharmaceuticals’s stock symbol?
The ticker symbol for Hikma Pharmaceuticals is HIK.
-
What is the current stock price of Hikma Pharmaceuticals?
As of 20-Nov-2026 the stock price of Hikma Pharmaceuticals is $22.06.
-
What is the current market cap of Hikma Pharmaceuticals?
The current market capitalization of Hikma Pharmaceuticals is $4.57B.
-
What is Hikma Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Hikma Pharmaceuticals is $3.42B.
-
Who are Hikma Pharmaceuticals’s competitors?
Lupin, Knight Therapeutics, Taro Pharmaceutical Industries, Dr. Reddy's, and Sandoz are some of the 28 competitors of Hikma Pharmaceuticals.
-
What is Hikma Pharmaceuticals’s annual earnings per share (EPS)?
Hikma Pharmaceuticals’s EPS for 12 months was $1.77.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process